Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7445482 + nucleos(t)ide
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
RO7445482, also known as xalnesiran or RG6346, is a liver-targeted, GalNAc-conjugated short-interfering RNA (siRNA) designed to inhibit hepatitis B virus (HBV) gene expression by targeting the S open reading frame of the HBV genome. When combined with a nucleos(t)ide analogue (e.g., entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide), it is under investigation as a combination therapy for chronic hepatitis B infection. The nucleos(t)ide component acts as a direct-acting antiviral that inhibits HBV reverse transcriptase, thus suppressing viral replication, while RO7445482 reduces HBV gene expression to lower viral antigen production. This combination aims to achieve a functional cure in chronic HBV-infected patients.
- Other names
- xalnesiran + nucleos(t)ide analogue
02
Targets
HBV (Hepatitis B virus)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on RO7445482 + nucleos(t)ide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7445482 + nucleos(t)ide.